TreyCatanzaro

Associate

Irvine + 1.949.553.7559

Connect:

Share

Trey Catanzaro practices corporate law with a focus on commercial real estate and financing transactions. He represents and advises large financial institutions, banks, and private companies in a wide variety of transactions.

Trey has represented clients in a broad range of industries, including real estate, technology, and life sciences. In addition, he has experience advising companies on corporate governance matters.

Trey maintains an active pro bono practice, assisting nonprofits in their corporate governance matters and representing survivors of human trafficking in obtaining various forms of relief.

Experience

  • Sumitomo acquires assets and rights related to lefamulin from NabrivaJones Day advised Sumitomo Pharma Co., Ltd. in the acquisition of assets from Nabriva Therapeutics plc and various wholly-owned subsidiaries. This acquisition includes assets from the U.S., Ireland, and Austria in support of the development, manufacture, marketing and commercialization of lefamulin in the People’s Republic of China, Hong Kong, Macau and Taiwan.
  • Astellas acquires Iveric bioJones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs.
  • Meridian Bioscience agrees to be acquired by SD Biosensor and SJL Partners in $1.53 billion all-cash transactionJones Day advised Meridian Bioscience, Inc. in its $1.53 billion all-cash acquisition by SD Biosensor and SJL Partners.
  • VSE Aviation acquires Precision Fuel ComponentsJones Day advised VSE Aviation Services, LLC, a subsidiary of VSE Corporation (NASDAQ: VSEC), in the acquisition of Precision Fuel Components LLC.
  • Organon makes strategic investment in Claria MedicalJones Day advised Organon in the strategic investment in Claria Medical, Inc. a privately-held company developing an investigational medical device being studied for use during minimally invasive laparoscopic hysterectomy.
    • View All

    February 2024 White Paper

    2023 Securities Litigation Year in Review

    February 2023 White Paper

    2022 Securities Litigation Year in Review

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.